Our country did not cede the nuclear race to the Soviet Union, and we cannot cede the biotechnology race to China now.
LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has filed ...
As the world prepares to feed an estimated 9.7 billion people by 2050, agriculture is rapidly transforming into one of the most critical and opportunity-rich sectors of the 21st century. No longer ...
LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing ...
Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security. As traditional drug-delivery approaches continue to face limitations, alternative methods ...
Welcome to Fierce Biotech’s fifth annual layoff tracker, a resource designed to keep pace with the sector’s steady stream of workforce reductions. In 2025, industry layoffs continued to rise year over ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Delhi Lieutenant Governor Taranjit Singh Sandhu on Monday said the younger generation has the potential to determine the course of India's progress in fields such as artificial intelligence, ...
Detailed price information for Geovax Labs Inc (GOVX-Q) from The Globe and Mail including charting and trades.
Linzess sales strength, apraglutide Phase III catalyst, FY2026 guidance and $5.37 target—read now for key upside drivers.
Protein language models are artificial intelligence tools which help engineer proteins with useful properties, including ...
Sagimet Biosciences Inc. gets a Buy rating as denifanstat targets MASH & acne; key Phase 3 catalysts and funding risks ahead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results